Stockscreener 앱 받기
15.00
0.99%
-0.15
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Trading (CAPR) With Integrated Risk Controls - Stock Traders Daily
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.9% – Time to Sell? - Defense World
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50 - Defense World
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 7.2%Still a Buy? - MarketBeat
Capricor Therapeutics Inc (CAPR) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Examining the Potential Price Growth of Capricor Therapeutics Inc (CAPR) - Knox Daily
Capricor Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Capricor Therapeutics Announces Upcoming Participation in Key Investor Conferences for 2025 - Nasdaq
Capricor (CAPR) to Showcase DMD Breakthrough at Three Elite Healthcare Conferences - StockTitan
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.1%Should You Sell? - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by SG Americas Securities LLC - Defense World
Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater
Gaining Ground: Capricor Therapeutics Inc (CAPR) Closes Lower at 14.33, Down -4.91 - The Dwinnex
BlackRock, Inc. Expands Stake in Capricor Therapeutics Inc - GuruFocus.com
Have you been able to find a good deal on Capricor Therapeutics Inc’s shares? - US Post News
Exosome Diagnostics & Therapeutics Market to Grow by USD 1.01 Billion (2025-2029) with Rising Research in Exosome Therapeutics Boosting the Market, Report on How AI is Driving Market TransformationTechnavio - The Malaysian Reserve
Capricor Therapeutics Inc [CAPR] Stock bought by Insider Nippon Shinyaku Co Ltd for $15.0 million - Knox Daily
Ready to Jump After Recent Trade: Capricor Therapeutics Inc (CAPR) - SETE News
Capricor wins key EU designations for the lead asset - MSN
Capricor Therapeutics Inc (NASDAQ:CAPR) Decline -1.05%, More Rally Possible - Marketing Sentinel
How to Take Advantage of moves in (CAPR) - Stock Traders Daily
5 DMD Candidates to Watch in 2025 - BioSpace
JPMorgan Chase & Co. Purchases 45,381 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
JPMorgan Chase & Co. Raises Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Magnus Financial Group LLC Invests $276,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Equities Analysts Set Expectations for CAPR FY2025 Earnings - Defense World
Analysts Set Expectations for CAPR FY2025 Earnings - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone - Yahoo Finance
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 53% CAGR over 5 years, surging 8.8% in the last week alone - Simply Wall St
Krilogy Financial LLC Makes New $287,000 Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Barclays PLC Has $552,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Barclays PLC Buys 18,724 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - MarketBeat
Now Is The Time To Build A Position In Capricor Therapeutics Inc (NASDAQ:CAPR) - Marketing Sentinel
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade - MSN
Will Capricor's Deramiocel Make History As The First Approved Treatment For DMD Cardiomyopathy? - RTTNews
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Growth in Short Interest - MarketBeat
Dilated Cardiomyopathy Pipeline Overview 2024: FDA Approvals and Key Developments | Vericel Corporation, AstraZeneca, Pfizer, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics - The Globe and Mail
Certain Common Stock of Capricor Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2025. - Marketscreener.com
Capricor's CAP-1002: A New Hope For Duchenne Muscular Dystrophy? - RTTNews
Application finalized for DMD cell therapy CAP-1002, now deramiocel - Muscular Dystrophy News
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - MSN
Capricor Therapeutics Completes BLA Submission for Deramiocel Treatment of Duchenne Muscular Dystrophy - Defense World
CAPR Stock Up On Completion Of Rolling Submission Of DMD Drug BLA - Barchart
Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Capricor stock reiterated at Buy at H.C. Wainwright By Investing.com - Investing.com Canada
0.27%
3.05%
자본화:
|
볼륨(24시간):